Ignyta Company Profile (NASDAQ:RXDX)

About Ignyta

Ignyta logoIgnyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic lymphoma kinase (ALK) proteins for the treatment of solid tumors. Its entrectinib is in Phase II/III of clinical development. Its taladegib is a small molecule and hedgehog or smoothened antagonist.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RXDX
  • CUSIP:
Key Metrics:
  • Previous Close: $8.70
  • 50 Day Moving Average: $6.40
  • 200 Day Moving Average: $5.98
  • 52-Week Range: $41,652,000.00 - $4.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.54
  • P/E Growth: 0.00
  • Market Cap: $362.37M
  • Outstanding Shares: 41,652,000
  • Beta: 1.44
Profitability:
  • Return on Equity: -90.70%
  • Return on Assets: -60.50%
Debt:
  • Debt-to-Equity Ratio: 0.24%
  • Current Ratio: 9.27%
  • Quick Ratio: 9.27%
Additional Links:
Companies Related to Ignyta:

Analyst Ratings

Consensus Ratings for Ignyta (NASDAQ:RXDX) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.00 (106.90% upside)

Analysts' Ratings History for Ignyta (NASDAQ:RXDX)
Show:
DateFirmActionRatingPrice TargetDetails
11/30/2016Jefferies Group LLCReiterated RatingBuy$20.00View Rating Details
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$32.00 -> $20.00View Rating Details
7/12/2016Credit Suisse GroupReiterated RatingBuyView Rating Details
6/23/2016J P Morgan Chase & CoInitiated CoverageOverweight$15.00View Rating Details
6/17/2016Cantor FitzgeraldReiterated RatingBuy$18.00View Rating Details
5/12/2016Leerink SwannReiterated RatingBuyView Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Ignyta (NASDAQ:RXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/7/2016Q3 2016($0.67)($0.56)ViewN/AView Earnings Details
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details
8/12/2014($0.26)($0.28)ViewN/AView Earnings Details
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ignyta (NASDAQ:RXDX)
Current Year EPS Consensus Estimate: $-2.60 EPS
Next Year EPS Consensus Estimate: $-2.46 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.63)($0.50)($0.57)
Q2 20162($0.67)($0.57)($0.62)
Q3 20162($0.67)($0.63)($0.65)
Q4 20162($0.73)($0.69)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ignyta (NASDAQ:RXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ignyta (NASDAQ:RXDX)
Insider Ownership Percentage: 15.10%
Institutional Ownership Percentage: 61.93%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016James A BristolDirectorBuy5,000$5.65$28,250.00View SEC Filing  
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00View SEC Filing  
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.00View SEC Filing  
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.00View SEC Filing  
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.52View SEC Filing  
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.00View SEC Filing  
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.00View SEC Filing  
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ignyta (NASDAQ:RXDX)
DateHeadline
News IconNumbers in Focus for Ignyta, Inc. (NASDAQ:RXDX) - BVN (NASDAQ:RXDX)
bvnewsjournal.com - February 24 at 5:13 AM
News IconChecking Indicator Levels for Ignyta Inc (RXDX) - Rives Journal (NASDAQ:RXDX)
rivesjournal.com - February 22 at 7:49 PM
News IconChart Watch for Ignyta, Inc. (NASDAQ:RXDX) - Midway Monitor (NASDAQ:RXDX)
midwaymonitor.com - February 22 at 7:49 PM
News IconStreet Session Update on Ignyta, Inc. (NASDAQ:RXDX) - Rockville Register (NASDAQ:RXDX)
rockvilleregister.com - February 18 at 6:42 PM
News IconReviewing the Levels for Ignyta, Inc. (NASDAQ:RXDX) - BVN (NASDAQ:RXDX)
bvnewsjournal.com - February 18 at 8:29 AM
News IconA Keen Look At The Chart For Ignyta, Inc. (RXDX) - NY Stock News (NASDAQ:RXDX)
nystocknews.com - February 18 at 8:29 AM
seekingalpha.com logoIgnyta, Inc. (RXDX) (NASDAQ:RXDX)
seekingalpha.com - February 10 at 11:25 PM
us.rd.yahoo.com logoIgnyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery (NASDAQ:RXDX)
us.rd.yahoo.com - February 10 at 11:25 PM
streetinsider.com logoIgnyta (RXDX) Announces Updated Results from Two Phase 1 Trials of Entrectinib Published in Cancer Discovery - StreetInsider.com (NASDAQ:RXDX)
www.streetinsider.com - February 10 at 1:21 AM
finance.yahoo.com logoIgnyta to Present at the LEERINK Partners 6th Annual Global Healthcare Conference (NASDAQ:RXDX)
finance.yahoo.com - February 8 at 11:49 PM
News IconIgnyta, Inc. (NASDAQ:RXDX) likely to see bigger moves on its earnings reaction day - Post Analyst (NASDAQ:RXDX)
postanalyst.com - February 6 at 8:37 AM
News IconTechnical Focus: Williams %R, ADX, and CCI Levels for Ignyta Inc. (RXDX) - Sherwood Daily (NASDAQ:RXDX)
sherwooddaily.com - February 1 at 3:15 AM
News IconInvestor Watch on Shares of Ignyta, Inc. (NASDAQ:RXDX) - The Tribune (NASDAQ:RXDX)
lakecitytribune.com - January 31 at 1:55 AM
News IconWatching Technical Levels on Shares of Ignyta Inc. (RXDX) - Sherwood Daily (NASDAQ:RXDX)
sherwooddaily.com - January 31 at 1:55 AM
News IconAre Insiders Bumping Up Their Positions in Ignyta, Inc. (NASDAQ:RXDX) - Wall Street Beacon (NASDAQ:RXDX)
wsbeacon.com - January 31 at 1:55 AM
News IconIgnyta Inc RXDX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RXDX)
www.bioportfolio.com - January 30 at 8:54 PM
News IconWhat is the Sell-side Saying About Ignyta, Inc. (NASDAQ:RXDX)? - Aiken Advocate (NASDAQ:RXDX)
aikenadvocate.com - January 28 at 7:47 PM
News IconTale of the Tape: Technical Recap for Ignyta Inc. (RXDX) - Rives Journal (NASDAQ:RXDX)
rivesjournal.com - January 28 at 7:47 PM
News IconCommit To Buy Ignyta At $2.50, Earn 8.2% Annualized Using Options (NASDAQ:RXDX)
www.stockoptionschannel.com - January 24 at 10:53 PM
News IconMA Levels in Review for Ignyta Inc. (RXDX) - Sherwood Daily (NASDAQ:RXDX)
sherwooddaily.com - January 24 at 8:00 AM
News IconTechnical Buzz on Ignyta, Inc. (NASDAQ:RXDX) - The Tribune (NASDAQ:RXDX)
lakecitytribune.com - January 24 at 8:00 AM
News IconUpside Alert: Delving into Shares of Ignyta, Inc. (NASDAQ:RXDX) - Prospect Journal (NASDAQ:RXDX)
prospectjournal.com - January 24 at 8:00 AM
News IconTracking Corporate Insiders: What Are They Doing With Ignyta, Inc. (NASDAQ:RXDX) - Wall Street Beacon (NASDAQ:RXDX)
wsbeacon.com - January 18 at 1:03 AM
News IconIgnyta, Inc. RXDX Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:RXDX)
www.bioportfolio.com - January 15 at 7:08 PM
finance.yahoo.com logoIgnyta to Present at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:RXDX)
finance.yahoo.com - January 5 at 6:08 AM
News IconCan This Stock Gain Traction: Ignyta, Inc. (NASDAQ:RXDX) - Prospect Journal (NASDAQ:RXDX)
prospectjournal.com - December 27 at 9:21 AM
4-traders.com logoIGNYTA, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:RXDX)
www.4-traders.com - December 24 at 12:50 AM
capitalcube.com logoIgnyta, Inc. :RXDX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016 (NASDAQ:RXDX)
www.capitalcube.com - December 16 at 2:49 AM
News IconStock Roaring Higher Pre-Bell: Ignyta, Inc. (NASDAQ:RXDX ... - Prospect Journal (NASDAQ:RXDX)
prospectjournal.com - December 13 at 8:02 PM
marketexclusive.com logoIGNYTA, INC. (NASDAQ:RXDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... - Market Exclusive (NASDAQ:RXDX)
marketexclusive.com - December 13 at 8:22 AM
insidermonkey.com logoIs Ignyta Inc (RXDX) A Good Stock To Buy? (NASDAQ:RXDX)
www.insidermonkey.com - December 12 at 7:44 PM
4-traders.com logoIgnyta : Appoints Steven L. Hoerter, Chief Commercial Officer of Agios Pharmaceuticals, Inc., to Board of Directors (NASDAQ:RXDX)
www.4-traders.com - December 12 at 9:21 AM
finance.yahoo.com logoIgnyta Appoints Steven L. Hoerter, Chief Commercial Officer of Agios Pharmaceuticals, Inc., to Board of Directors (NASDAQ:RXDX)
finance.yahoo.com - December 12 at 9:21 AM
biz.yahoo.com logoIGNYTA, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:RXDX)
biz.yahoo.com - December 12 at 9:21 AM
News IconADX in View on Shares of Ignyta Inc. (RXDX) - Yankee Analysts (NASDAQ:RXDX)
yankeeanalysts.com - December 10 at 6:52 PM
News IconTechnicals in Focus for Ignyta Inc. (RXDX) - Yankee Analysts (NASDAQ:RXDX)
yankeeanalysts.com - December 10 at 12:34 AM
biz.yahoo.com logoIGNYTA, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (NASDAQ:RXDX)
biz.yahoo.com - December 7 at 8:47 AM
News IconAre There Catalysts to Propel This Stock Forward: Ignyta, Inc. (NASDAQ:RXDX) - Prospect Journal (NASDAQ:RXDX)
prospectjournal.com - December 6 at 8:51 AM
streetinsider.com logoIgnyta (RXDX) Announces Encouraging RXDX-105 Phase 1/1b Data; ORR of 56% Noted (NASDAQ:RXDX)
www.streetinsider.com - December 2 at 7:16 PM
uk.finance.yahoo.com logoIgnyta Announces Compelling Phase 1/1b Clinical Data on RXDX-105, Its VEGFR-Sparing RET Inhibitor, at the 2016 EORTC-NCI-AACR Annual Meeting (NASDAQ:RXDX)
us.rd.yahoo.com - December 2 at 7:16 PM
uk.finance.yahoo.com logoLate-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting (NASDAQ:RXDX)
us.rd.yahoo.com - December 2 at 7:16 PM
us.rd.yahoo.com logo5:13 am Ignyta presents Late-Breaking data for Entrectinib combination regimen; shows ability to overcome resistance to TRK inhibition (NASDAQ:RXDX)
us.rd.yahoo.com - December 2 at 7:16 PM
businesswire.com logoIgnyta Announces Compelling Phase 1/1b Clinical Data on RXDX-105, Its VEGFR-Sparing RET Inhibitor, at the 2016 ... - Business Wire (press release) (NASDAQ:RXDX)
www.businesswire.com - December 2 at 11:46 AM
streetinsider.com logoIgnyta (RXDX) to Offer Entrectinib Combo Update in TRK Inhibition in Late-Breaking Presentation at 2016 EORTC-NCI ... - StreetInsider.com (NASDAQ:RXDX)
www.streetinsider.com - December 2 at 11:46 AM
News IconInvestor Arena: Keeping an Eye on Ignyta Inc. (RXDX) - Yankee Analysts (NASDAQ:RXDX)
yankeeanalysts.com - December 2 at 11:46 AM
News IconIgnyta, Inc. (RXDX) Under Analyst Spotlight - UK Market News (NASDAQ:RXDX)
www.ukmarketnews.co.uk - December 1 at 7:33 PM
streetinsider.com logoIgnyta (RXDX) Announces Encouraging RXDX-105 Phase 1/1b Data; ORR of 56% Noted - StreetInsider.com (NASDAQ:RXDX)
www.streetinsider.com - December 1 at 8:12 AM
4-traders.com logoIGNYTA, INC. (NASDAQ:RXDX) Files An 8-K Regulation FD Disclosure (NASDAQ:RXDX)
www.4-traders.com - November 29 at 3:10 PM
marketexclusive.com logoIGNYTA, INC. (NASDAQ:RXDX) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:RXDX)
marketexclusive.com - November 29 at 7:46 AM
uk.finance.yahoo.com logoIgnyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting (NASDAQ:RXDX)
uk.finance.yahoo.com - November 29 at 7:46 AM

Social

What is Ignyta's stock symbol?

Ignyta trades on the NASDAQ under the ticker symbol "RXDX."

Where is Ignyta's stock going? Where will Ignyta's stock price be in 2017?

6 brokerages have issued 12-month price objectives for Ignyta's stock. Their predictions range from $15.00 to $20.00. On average, they expect Ignyta's share price to reach $18.00 in the next year.

When will Ignyta announce their earnings?

Ignyta is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Ignyta stock?

Here are some recent quotes from research analysts about Ignyta stock:

  • According to Zacks Investment Research, "Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California. " (1/11/2017)

  • Jefferies Group LLC analysts commented, "ENA preclinical posters on RXDX-106 showed encouraging activity in both immuno-oncologic modulation and direct tumor targeting. These initial data support further development of ‘106 and we would look for more details at Dec 1 conference call. Incremental preclinical data of ‘105 and entrectinib were also presented." (11/30/2016)

Who owns Ignyta stock?

Ignyta's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (5.42%), Armistice Capital LLC (4.80%), Frazier Management LLC (2.28%), Artal Group S.A. (2.04%), FMR LLC (1.26%) and State Street Corp (1.02%). Company insiders that own Ignyta stock include Alexander W Casdin, City Hill Venture Partners I,, Jacob Chacko, James A Bristol, James L Freddo, Jonathan E Lim and Robert Wild.

Who sold Ignyta stock? Who is selling Ignyta stock?

Ignyta's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC.

Who bought Ignyta stock? Who is buying Ignyta stock?

Ignyta's stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Boxer Capital LLC, State Street Corp, Dimensional Fund Advisors LP, Teza Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought Ignyta stock in the last two years include Alexander W Casdin, City Hill Venture Partners I,, Jacob Chacko, James A Bristol, James L Freddo, Jonathan E Lim and Robert Wild.

How do I buy Ignyta stock?

Shares of Ignyta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ignyta stock cost?

One share of Ignyta stock can currently be purchased for approximately $8.70.

Ignyta (NASDAQ:RXDX) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Earnings History Chart

Earnings by Quarter for Ignyta (NASDAQ:RXDX)

Dividend History Chart

Dividend Payments by Quarter for Ignyta (NASDAQ:RXDX)

Last Updated on 2/26/2017 by MarketBeat.com Staff